Table 2.
Inhibitory effect of JFK on LECs formation.
| Group | Inhibition rate (%) | ||
|---|---|---|---|
| SDF-1 | VEGF-C | SDF-1 + VEGF-C | |
| BS | 0.00 ± 14.40 | 0.00 ± 5.61 | 0.00 ± 18.29 |
| JFK-1 | 44.10 ± 6.80∗ | 38.89 ± 6.30∗ | 58.82 ± 12.37∗ |
| JFK-2 | 60.57 ± 4.51∗ | 79.71 ± 1.31∗ | 76.06 ± 9.54∗ |
| JFK-3 | 82.79 ± 6.44∗ | 89.14 ± 1.43∗ | 91.16 ± 2.31∗ |
| AMD | 93.73 ± 0.60∗ | ||
| Len | 87.18 ± 5.80∗ | ||
| Len + AMD | 96.33 ± 0.60∗ | ||
BS, blank serum; JFK-1, JFK-2, and JFK-3, the serums prepared from rats by oral administration of JFK at doses of 1.8, 3.6, and 7.2 g/kg, respectively; AMD, AMD3100; Len, Lenvatinib. The inhibition rates of BS groups were pegged as 0.00%, and others were calculated relative to it. Data were expressed as mean ± SD, n = 3. ∗ p < 0.01 compared with the BS group, respectively.